Ongoing launch of CASGEVY ® continues to gain momentum; new cell patient collection initiations expected to significantly grow in 2025- -More than 50 authorized treatment centers (ATCs) activated ...

From packable sleeping pads to ultracomfortable air beds, we tested and found the best camping mattresses and sleeping pads ...

Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly ...

1 The technology is based on low-coherence interferometry, and it measures the time delay and intensity of light back-reflected from tissue structures at various depths compared with a reference ...

In a report released yesterday, Liisa Bayko from Evercore ISI maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), with ...

Vertex just won approval for a drug to treat one of the most common health problems -- pain. The biotech company is offering an option for patients and doctors who don’t want to go for ...

The FDA recently approved Journavx for treating acute pain. This approval is tremendously important for Vertex Pharmaceuticals. The biotech company has also received other good news over the last ...

Scotiabank raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $450 from $433 and keeps a Sector Perform rating on the shares. The company had a strong Q4, with revenue beating ...

UnitedHealthcare likely to cover Vertex’s pain drug Vertex Pharmaceuticals received FDA approval for a new non-opioid pain drug, marketed as Journavx, and it appears the nation’s largest ...

HOUSTON, January 22, 2025--(BUSINESS WIRE)--Vertex Energy, Inc. ("Vertex" or the "Company"), a leading specialty refiner and marketer of high-quality refined products, together with its affiliates ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...